➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Johnson and Johnson
Express Scripts
Baxter

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for NNZ-2591


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug NNZ-2591?

NNZ-2591 is an investigational drug.

There have been 12 clinical trials for NNZ-2591. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2013.

The most common disease conditions in clinical trials are Syndrome, Brain Injuries, and Rett Syndrome. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited, rettsyndrome.org, and Texas Children's Hospital.

There are fourteen US patents protecting this investigational drug and thirty-six international patents.

Recent Clinical Trials for NNZ-2591
TitleSponsorPhase
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman SyndromeNeuren Pharmaceuticals LimitedPhase 2
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)Neuren Pharmaceuticals LimitedPhase 2
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)Neuren Pharmaceuticals LimitedPhase 2

See all NNZ-2591 clinical trials

Clinical Trial Summary for NNZ-2591

Top disease conditions for NNZ-2591
Top clinical trial sponsors for NNZ-2591

See all NNZ-2591 clinical trials

US Patents for NNZ-2591

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NNZ-2591 ⤷  Free Forever Trial Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) ⤷  Free Forever Trial
NNZ-2591 ⤷  Free Forever Trial Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) ⤷  Free Forever Trial
NNZ-2591 ⤷  Free Forever Trial Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) ⤷  Free Forever Trial
NNZ-2591 ⤷  Free Forever Trial Composition and method for treating neurological disease Osmotica Kereskedelmi es SzolgaltatoKorlatolt Felelossegu Tarsasag (Budapest, HU) ⤷  Free Forever Trial
NNZ-2591 ⤷  Free Forever Trial Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Felelossegu Tarsasag (Budapest, HU) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NNZ-2591

Drugname Country Document Number Estimated Expiration Related US Patent
NNZ-2591 Denmark DK3024463 2033-07-25 ⤷  Free Forever Trial
NNZ-2591 European Patent Office EP3024463 2033-07-25 ⤷  Free Forever Trial
NNZ-2591 Spain ES2797374 2033-07-25 ⤷  Free Forever Trial
NNZ-2591 Croatia HRP20201002 2033-07-25 ⤷  Free Forever Trial
NNZ-2591 Hungary HUE049302 2033-07-25 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
AstraZeneca
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.